linjc16/ctgov huggingface dataset:
Enhancing Uptake of Family Planning Services by HIV-Infected Women Attending the PMTCT Program

Study Overview
=================
Brief Summary
-----------------
A specific organized program utilizing peers in the PMTCT clinic who provide family planning information and support to HIV infected mothers was compared to providing standard family planning messages currently used in the clinic.

Detailed Description
-----------------
A planned group education structural intervention utilizing peers in the PMTCT clinic who provide family planning information and support to HIV infected mothers was compared to the standard of care which consisted of providing standard family planning messages to women attending the PMTCT Clinic. The study had two phases. The Formative Phase consisted of six focus group discussions and six in depth interviews. In the Implementation Phase, patient attendance and family planning uptake summaries for during implementation were monitored and summarized daily. Weekly average summaries were considered as time points.

Official Title
-----------------
Enhancing Uptake of Family Planning Services by HIV Infected Women Attending the Postpartum Component of the PMTCT Program in Mulago National Referral Hospital, Kampala, Uganda Utilizing HIV-Infected Peers as Family Planning Champions

Conditions
-----------------
Contraception

Intervention / Treatment
-----------------
* Behavioral: Group Education


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: This being a program based intervention, all HIV positive mothers who utilize the PMTCT and post natal clinic during the study period will be enrolled. Exclusion Criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Group education<br>Non pregnant HIV+ mothers were exposed to a structured educational intervention on family planning facilitated by Peer Champions. | Behavioral: Group Education<br>* Structured group education on family planning facilitated by Peer Champions<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| proportion of mothers who took up Family Planning |  | weekly for one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HIV, PMTCT
Genetic Biomarker Discovery for Metastatic Prostate Cancer

Study Overview
=================
Brief Summary
-----------------
Biomarkers from circulating cell-free tumor DNA in peripheral blood will identify patients with metastatic prostate cancer diagnosed with C11 choline PET/CT who will benefit from metastasis-directed radiation, ablative therapies, and/or surgery. Tissue and blood will be collected before treatment. If patients receive androgen deprivation, then blood will be collected after neoadjuvant androgen deprivation but before radiation, ablative therapies, or surgery. Subsequent samples will be obtained at 3 months and 6 months following treatment, after which no further patient contact will occur.

Official Title
-----------------
ROR1751: Genetic Biomarker Discovery for Metastatic Prostate Cancer

Conditions
-----------------
Prostate Cancer

Intervention / Treatment
-----------------
* Other: Blood draw
* Procedure: Tissue biopsy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Men age 18 years old and older. Histologically proven diagnosis of prostate cancer. Radiographic evidence of non-regional lymph node involvement, pelvic lymph node recurrence, and/or bone metastases. Requiring a clinically directed biopsy or resection of tumor at Mayo Clinic Rochester. Receiving local therapy for metastatic disease with radiation, ablative therapies, and/or surgery at Mayo Clinic Rochester. Willingness to provide blood sample prior to receipt of treatment, as well as after neoadjuvant androgen deprivation therapy and at 3 months and 6 months after radiation, ablation, or surgery. Absence of a second active malignancy. An understanding of the protocol and its requirements, risks, and discomforts. The ability and willingness to sign an informed consent. Exclusion Criteria: Inability on the part of the patient to understand the informed consent or be compliant with the protocol. History of a serious or life-threatening allergic reaction to local anesthetics (i.e., lidocaine, xylocaine).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Men >18 years old with metastatic prostate cancer<br> | Other: Blood draw<br>* (2) 10 mL tubes will be collected<br>Procedure: Tissue biopsy<br>* Tissue biopsy of metastatic tissue if undergoing clinical care-directed biopsy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Detect cell-free tumor DNA in patients with metastatic prostate cancer | tissue biopsy | prior to treatment | 
| Calculate cell-free tumor DNA in relation to metastasis-directed radiation and androgen deprivation therapy (ADT) | blood draw | before and immediately after ADT and at 3 months and 6 months after radiation |
Association Between Fractional Exhaled Nitric Oxide and Asthma Control

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine mean or median of fractional exhaled nitric oxide (FeNO) in Thai atopic asthmatic patients that divided into subgroups due to level of asthma control according to the global initiative for asthma guideline.

Detailed Description
-----------------
From many previous studies, fractional exhaled nitric oxide (FeNO) has many benefits such as non-invasive, easily to perform, less time consume, has direct association with severity of inflammation of bronchial trees and sputum eosinophils, has benefit for diagnosis and monitoring the treatment in asthmatic patients. In Thailand, this field of study is less extend, especially in children population. We hypothesized that in uncontrolled or partly controlled group may have high level of fractional exhaled nitric oxide (FeNO) than controlled group. It is therefore desirable to examine the association between fractional exhaled nitric oxide (FeNO) and level of asthma control among atopic asthmatic Thai children and will be the main objective of this research.

Official Title
-----------------
Association Between Fractional Exhaled Nitric Oxide and Asthma Control

Conditions
-----------------
Bronchial Asthma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: clinical diagnosis of atopic bronchial asthma follow up in clinic of allergy and clinical immunology, Siriraj hospital Exclusion Criteria: smoker or past history of smoking has chronic disease eg. HIV infection, pulmonary hypertension, systemic lupus erythematosus, liver cirrhosis, gastroesophageal reflux, COPD, bronchiectasis drink ethanol within 48 hours before enrollment history of upper or lower respiratory tract infection within 6 weeks before enrollment drink caffeine within day before enrollment during pregnancy history of systemic steroid use within 8 weeks before enrollment

Ages Eligible for Study
-----------------
Minimum Age: 7 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| fractional exhaled nitric oxide level |  | 10 minutes (average time), on the day of enrollment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| scores of asthma control test: ACT |  | 5 minutes (average time), on the day of enrollment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Bronchial asthma, level of control of asthma, fractional exhaled nitric oxide (FeNO), asthma control test (ACT)
Effectiveness and Safety of Viagra in Men With ED and LUTS Due to Benign Prostatic Hyperplasia (BPH)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether Viagra is effective in treating erectile dysfunction and lower urinary tract symptoms in men affected by both conditions.

Official Title
-----------------
A Multicenter, Randomized, Parallel Group, Double-blind, Placebo-controlled Flexible Dose Study With and Open-label Extension to Assess the Efficacy and Safety of Viagra (Sildenafil Citrate) in the Treatment of Men With Erectile Dysfunction (ED) and Concomitant Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH) in the United States

Conditions
-----------------
Impotence

Intervention / Treatment
-----------------
* Drug: Viagra
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: clinical diagnosis of erectile dysfunction (ED) lower urinary tract symptoms (LUTS) Exclusion Criteria: previous prostate surgery or invasive intervention for BPH active urinary tract disease

Ages Eligible for Study
-----------------
Minimum Age: 45 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Viagra|nan|
|Drug: Placebo|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparison of change in EF domain of IIEF at Week 12 between Viagra and placebo |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Effect on: IPSS Effect on IPSS QoL Orgasmic Function |  |  | 
| Sexual Desire Intercourse Satisfaction and Overall Satisfaction domains of IIEF Qmax by uroflometry |  |  | 
| Event Log Variables |  |  |
The Liberatory Maneuver for the Treatment of Benign Paroxysmal Positional Vertigo (BPPV)

Study Overview
=================
Brief Summary
-----------------
This study is being done because the investigators would like to know how effective the Liberatory maneuver is in treating benign paroxysmal positional vertigo (BPPV).

Detailed Description
-----------------
BPPV is a problem with the inner ear that causes brief periods of vertigo triggered by changes in the position of the head such as rolling, looking up, or bending down. BPPV is presently thought to be caused by small pieces of debris or crystals becoming displaced within the inner ear. It can be treated by moving the patient through a series of positions called a maneuver. There are 2 different maneuvers currently used to treat BPPV by the clinician called the liberatory maneuver and the canalith repositioning procedure. We would like to determine how effective the liberatory maneuver is in the treatment of BPPV compared to a placebo maneuver.

Official Title
-----------------
The Liberatory Maneuver for the Treatment of Benign Paroxysmal Positional Vertigo: A Randomized Controlled Trial

Conditions
-----------------
Vertigo, Vestibular Disease

Intervention / Treatment
-----------------
* Other: Liberatory Maneuver
* Other: Placebo maneuver


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: BPPV involving the posterior canal on only one side Exclusion Criteria: No other canals involved (anterior canal or lateral canal), no central nervous system disorder, and no other medical condition that would not enable the individual to have the maneuver done.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Liberatory Maneuver<br>Liberatory Maneuver | Other: Liberatory Maneuver<br>* 3 cycles of the liberatory maneuver initial session.<br>* Other names: Semont Maneuver;|
| Placebo Comparator: Placebo Maneuver<br>Placebo Maneuver | Other: Placebo maneuver<br>* 3 cycles placebo maneuver initial session.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Negative Dix-Hallpike maneuver |  | 1-2 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Self reported willingness to move |  | 1-2 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Benign Paroxysmal Positional Vertigo, BPPV, PC, BPPN, Vertigo
Bedside Ultrasonography in Acute Patients With Suspected Kidney Involvement

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to evaluate the accuracy and implications of the diagnoses and treatment determined by bedside ultrasonography (b-US) of the kidneys compared to current clinical assessment. Potentially diagnosing patients faster and avoiding missing conditions leading to readmission or unnecessary radiation from computed tomography (CT). This study evaluates the use of b-US as a supplement to clinical evaluation, in an unselected group of patients in the emergency department (ED) with signs of kidney involvement. The b-US of the kidneys is performed by a medical student certified in this technique. The evaluation will be based on data collected from a Danish hospital (Odense University Hospital, OUH) in autumn 2018.

Official Title
-----------------
Bedside Ultrasonography in Acute Patients With Suspected Kidney Involvement

Conditions
-----------------
Hydronephrosis, Pyelonephritis, Urosepsis

Intervention / Treatment
-----------------
* Diagnostic Test: bedside ultrasonography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Suspicion of urinary tract infection and one or more of the following: Flank pain Fever Symptoms when voiding Creatinine elevation or 20% elevation from known creatinine level elevation Exclusion Criteria: Age < 18 years Radiological ultrasonographic examination already performed Patients who are not able to consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: bedside ultrasonography|Patients suspicious to urinary tract infection with kidney involvement are being examined by ultrasonography to detect hydroneprhosis. The treating clinicians fill out questionnaires to validate the impact of the bedside ultrasonography on the patient care and treatment.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ultrasonographic hydronephrosis | Ultrasonographic hydronephrosis defined by > 1cm pelvic dilation | All included patient undergo bedside ultrasonography within 4 hours after admission | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical consequence of bedside ultrasonographic result | Clinicians responsible for the primary clinical assessment determine treatment and further examinations before and after the ultrasonographic results. | Within 4 hours after admission | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
bedside ultrasonography, emergency department
An Open-label Extension to Evaluate the Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease

Study Overview
=================
Brief Summary
-----------------
The goal of this research study is to evaluate, in the open-label extension phase, the safety and efficacy of the rivastigmine transdermal patch in patients with probable Alzheimer's Disease

Official Title
-----------------
An Open-label Extension to Evaluate the Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease

Conditions
-----------------
Alzheimer's Disease

Intervention / Treatment
-----------------
* Drug: Rivastigmine Transdermal Patch


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who fulfilled the inclusion and exclusion criteria as listed in the study CENA713D2320 and have completed the double-blind treatment phase on study medication without significant protocol violations.

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Rivastigmine Transdermal Patch|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety and tolerability as measured by adverse events, vital signs and skin irritation for up to 28 weeks treatment |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in cognition from baseline (week 24 of the double blind phase) at week 52 |  |  | 
| Clinical global impression of change from baseline at week 52 |  |  | 
| Change in activities of daily living from baseline at week 52 |  |  | 
| Change in behavioral symptoms from baseline at week 52 |  |  | 
| Change in executive function from baseline at week 52 |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Alzheimer's disease, Dementia
Fluorescent Thoracoscopy Used in Surgery for Palmar Hyperhidrosis

Study Overview
=================
Brief Summary
-----------------
T3/T4 endoscopic thoracic sympathicotomy is a widely accepted and effective treatment for primary palmar hyperhidrosis. However, sympathetic ganglions are invisible with traditional thoracoscopy and until now, the location of ganglions are confirmed by rib indirectly. The team from thoracic department of Peking University People's Hospital discovered that the sympathetic ganglions can be visualized with fluorescent thoracoscopy. Thus, investigators want to apply fluorescent thoracoscopy in sympathicotomy of palmar hyperhidrosis, to conduct a more precise operation and compare the efficiency of the novel and traditional methods.

Official Title
-----------------
Fluorescent Thoracoscopy Used in Surgery for Palmar Hyperhidrosis

Conditions
-----------------
Palmar Hyperhidrosis

Intervention / Treatment
-----------------
* Procedure: Near-Infrared Imaging Thoracoscopy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosed with primary palmar hyperhydrosis. Accept surgical treatment and signed informed consent. Exclusion Criteria: Liver dysfunction. Allergic to indocyanine green. Can't tolerate thoracoscopic surgery.

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| palmar hyperhidrosis<br>VATS R4 Sympathicotomy performed on all patients. Fluorescent thoracoscopy was used to identify the shifting mode of sympathetic ganglions. | Procedure: Near-Infrared Imaging Thoracoscopy<br>* Sympathicotomy performed by near-infrared imaging thoracoscopy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Anatomical variation of the sympathetic ganglions | Record the spatial relationship between sympathetic ganglions and ribs, for example: T3/R4 represents the T3 sympathetic ganglion is located on the 4th rib. | during surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Improvement of palmar sweating | Use questionnaire including 3 descriptive names of scale ( over dry, comfortable and wet) to record the surgical effect on palmar sweating. | 1 month after surgery | 
| Degree of compensatory hyperhidrosis | Use questionnaire including 4 descriptive names of scale ( none, mild, moderate and severe) to record the side effect (compensatory hyperhidrosis) of this surgery. | 1 month after surgery |
Measurement of MRP2 Function Using Urinary Coproporphyrins

Study Overview
=================
Brief Summary
-----------------
Human Multidrug Related Protein 2 (MRP2) excretes several drugs and could therefore modulate their elimination. Individual's MRP2 activity is under genetic control. Thus it would be very useful to get an easily measurable biomarker reflecting individual's MRP2 activity. We aimed to investigate the ratio of urinary coproporphyrins I and III (UCP(I/I+III), known to be increased in patients with mutations in MRP2/ABCC2 gene.

Official Title
-----------------
Evaluation of the Ratio of Urinary Coproporphyrins I and III as a Potential Biomarker of MRP2 Function in Man

Conditions
-----------------
Healthy Subjects

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy > 18 y Affiliated to an health insurance Exclusion Criteria: Patient not able to understand or to comply to the protocol

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Healthy volunteers >18y, 20 male, 20 female | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Urinary coproporphyrins (I/I+III)ratio |  | End of three 24-hours periods | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ABCC2 polymorphisms |  | At the time of entering in the study | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Healthy